Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the pathological and molecular responses associated with tr...
Guardado en:
Autores principales: | Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine L. McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee Zehngebot, Heather Allen, Linda Bosserman, Brian DiCarlo, April Kennedy, Armando Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df55 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
por: Jason J Zoeller, et al.
Publicado: (2021) -
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
por: Hurvitz SA, et al.
Publicado: (2012) -
Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
por: Machado M, et al.
Publicado: (2012) -
Solo, dúo, trío
por: Menanteau,Álvaro
Publicado: (2004) -
trioPhaser: using Mendelian inheritance logic to improve genomic phasing of trios
por: Dustin B. Miller, et al.
Publicado: (2021)